Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), an emerging growth company incorporated in Delaware, filed this Form 8-K on November 3, 2025. The report details a private placement transaction closed on November 4, 2025, involving the issuance of pre-funded warrants to raise capital.
Key Financial Metrics
- Gross Proceeds: Approximately $2.5 million from the sale of pre-funded warrants.
- Securities Issued: Pre-funded warrants to purchase up to 625,156 shares of common stock.
- Exercise Price: $0.001 per share.
- Placement Agent Fee: 4% of gross proceeds paid to WestPark Capital, Inc.
- Net Proceeds: The filing does not provide a clear value for net proceeds after deducting placement agent fees and offering expenses.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and a Placement Agency Agreement. The company agreed to issue and sell pre-funded warrants in a private placement exempt from registration under Section 4(a)(2) of the Securities Act. This transaction increases the potential share count upon exercise and alters the company's capital structure.
Outlook, Risks, and Unusual Items
- Registration Obligation: The Company must file a registration statement within 15 days of the agreement (by November 18, 2025) and have it declared effective within 45 days (or 75 days if reviewed by the SEC) to allow resale of the underlying shares.
- Lock-Up Period: The Company is restricted from issuing or announcing the issuance of any common stock or equivalents for 15 days following the closing of the offering.
- Beneficial Ownership Limit: The warrant holder cannot exercise if it would beneficially own more than 4.99% of outstanding shares, though this can be increased to 9.99% with 61 days' prior notice.
- Management Commentary: The filing contains standard legal disclaimers regarding representations and warranties, noting they are not characterizations of the actual state of facts for general investors.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 4% placement fee and other offering expenses.
- Confirm the filing date and effectiveness status of the required resale registration statement.
- Review the identity of the Purchaser to assess potential concentration of ownership.
- Monitor the 15-day lock-up period for any additional equity issuances.
- Check subsequent filings for the use of proceeds and impact on cash runway.